Receptor Tyrosine Kinase Treatment Market Size & Share, by Product Type (Epidermal Growth Factor Receptor [EGFR] Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor [VEGFR] Tyrosine Kinase Inhibitors); Application (Lung Cancer, Breast Cancer, Renal Cell Cancer); Distribution (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Global Receptor Tyrosine Kinase Treatment Market Definition

Kinase inhibitors are a type of medicine that works by adding a phosphate group to protein to block the function of kinases. The suppression of kinases could have detrimental effects on a cell, leading to its death or impaired function. Kinases are involved in many biological processes, including cell proliferation, differentiation, cell cycle, and apoptosis.

As a result, these medications are most frequently utilized to treat a range of illnesses where this kind of disturbance is required to be present, including cancer, diabetes, and inflammation. Further kinase inhibitors are divided into receptor tyrosine kinase treatment and non-receptor tyrosine kinase treatment.

Amongst which, receptor tyrosine kinase (RTK) is one of the popular subclass of tyrosine kinase therapeutics. It has greatly advanced the understanding of cancer cell genetics as well as cellular and structural biology. Growth, motility, differentiation, and metabolism are just a few of the numerous cellular activities that receptor tyrosine kinases (RTKs) are involved in. Early response brought forth by TKI inhibition has increased survival chances and decreased morbidity.

Global Receptor Tyrosine Kinase Treatment Market: Key Insights

Global Receptor Tyrosine Kinase Treatment Market Size, Forecast, and Trend Highlights Over 2023 – 2035

The global receptor tyrosine kinase treatment market is estimated to garner a revenue of ~USD 110 Billion by the end of 2035 by growing at a CAGR of ~8% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of ~USD 57 Billion in the year 2022. The growth of the market can be attributed by growing cases of cancer all around the world. According to the World Health Organization, nearly 10 million deaths, or nearly one in six deaths, were caused by cancer in 2020, making it the top cause of death globally. Hence the demand for targeted therapies are growing. Targeted therapy includes tyrosine kinase inhibitors (TKIs). A targeted therapy lessens the harm done to healthy cells by locating and attacking particular cancer cell types. Hence, the adoption of TKIs is growing extensively. Further, among this the receptor tyrosine kinase treatment is popular. Cell growth and survival are two important processes that are regulated by receptor tyrosine kinase (RTK) activity. But it has been demonstrated that dysregulation of RTK correlates with the onset and spread of many malignancies, and it has been discovered in a variety of tumors. As a result, RTK has gained popularity as a therapeutic target.

Additionally, there has been growing initiatives taken to spread awareness regarding the diagnosis and availability of cancer treatment. Also, governments are initiating their efforts and making healthcare facilities accessible to people. Further, since there has been growing prevalence of cancer, the R&D activities are also on boost. Moreover, the market for receptor tyrosine kinase treatment is being driven by the existence of patient support programmes. A lot of public and private organizations are concentrating on offering monetary and medical support for the therapy of numerous cancer symptoms. As a result, a large number of patients are receiving the necessary care, which is growing the patient base. These initiatives aid patients in sticking to their treatment plans.

Global Receptor Tyrosine Kinase Treatment Market: Growth Drivers and Challenges

Growth Drivers

• Surge in Prevalence of Obesity - Over 1 billion individuals, including 650 million adults, 340 million teenagers, and 39 million children, are obese worldwide. This figure is still rising. According to the WHO, 167 million adults and children would have worse health by 2025 as a result of being overweight or obese. Obesity and overweight could alter the body in ways that contribute to the development of cancer. Long-lasting inflammation, elevated levels of insulin, insulin-like growth factor, and sex hormones are a few instances of these changes. The more additional weight a person puts on and the longer they are overweight, the higher their risk of developing cancer is. For instance, obesity and being overweight are associated with a greater risk of 13 different types of cancer.

• Growing Investment in Healthcare - The predicted cost of healthcare in India in 2020 was about 190 billion US dollars and this amount is estimated rise to about 370 billion US dollars.

• Clinical Approval of Kinase Inhibitors - Up until September 2021, the FDA approved about 72 small molecule kinase inhibitor medicines, and other regulatory bodies also approved more inhibitors throughout that time.

• Upsurge in Investment by Pharmaceutical Companies on R&D- Globally, the pharmaceutical sector invested over 230 billion dollars on research and development in 2021.

• Rising Preference for Oral Drugs - Approximately 59% of established small-molecule medicinal compounds that are commercially accessible are given orally.

Challenges

• High cost of tyrosine kinases therapies - A lack of qualified personnel who are unable to give patients the treatment they need is limiting the growth of the receptor tyrosine kinase treatment market on a global scale. Market expansion in the R&D sector is significantly constrained by higher expenditures and challenging regulatory approval processes. Additionally, a corollary of the high development costs of medications is a higher market price for the drug following approval. The National Cancer Institute estimates that the average cost of medical care and medications after a cancer diagnosis would be more than USD 40,000 in 2022. The high expense of the treatment has thus up until a certain point limited market penetration.
• Lack of funds for R&D activities
• Challenges faced by clinical trials for commercialization of tyrosine kinase inhibitors

Global Receptor Tyrosine Kinase Treatment Market Segmentation

The global receptor tyrosine kinase treatment market is segmented and analyzed for demand and supply by application into lung cancer, breast cancer, renal cell cancer, and others. Out of which the breast cancer segment is anticipate to hold the largest market share over the forecast period. The growth of the segment can be attributed to growing cases of breast cancer all across the world. Breast cancer is the second most common type of cancer and the most common in females, with about 20% of all cases to be HER-2 positive. As a result, numerous HER2-targeted treatments have been introduced lately, including the TKIs lapatinib, neratinib, tucatinib, and pyrotinib. However, TKIs have proven to be successful in this situation where the outlook is still grim and there are few other therapy choices.

The global receptor tyrosine kinase treatment market is also segmented and analyzed for demand and supply by product type into epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, platelet-derived growth factor receptor (PDGFR) tyrosine kinase inhibitors, and others. Amongst these segments, the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors segment is anticipated to grow at the highest rate over the forecast period. This growth of the segment can be attributed to rising cases of lung cancer all across the world. Hence the demand for this treatment is estimated to increase has it has been observed to be one of the efficient treatment for lung cancer. Further, it is also used for treatment for various other cancers which includes, breast cancer, cervical cancer and more.

Our in-depth analysis of the global receptor tyrosine kinase treatment market includes the following segments:

Global Receptor Tyrosine Kinase Treatment Market Regional Synopsis

The North American receptor tyrosine kinase treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035, backed by high prevalence of cancer in the region, increasing R&D activities with tyrosine kinase inhibitors, and the presence of prominent market players, with the U.S. dominating over the region. In 2020, approximately 1.8 million new cases of cancer were diagnosed in the U.S. with a mortality rate higher among men than women. Additionally, there has been growing investment on R&D in order to develop novel cancer treatment in this region. Hence, this factor is also anticipated to boost the market growth in this region.

Moreover, Asia-Pacific region is expected to witness the fastest market growth owing to the boost in prevalence of cancer all across this region. Between 2012 and 2018, the number of newly diagnosed cancer cases in Asia-Pacific rose from about 5 million to approximately 8 million. The region's population is ageing at a record-breaking rate, which is a major factor in this development. Hence, there has been rise in research and development activities for cancer and related diseases in this region, which is expected to boost the market further. Moreover, increased use of kinase inhibitors for newer applications in emerging economies such as China and India would provide new opportunities for market players to invest in the region, further boosting the market growth.

Top Featured Companies Dominating the Global Receptor Tyrosine Kinase Treatment Market

• Bristol-Myers Squibb Company
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 
• Boehringer Ingelheim GmbH
• Eton Bioscience, Inc.
• GlaxoSmithKline plc
• Merck KGaA
• AstraZeneca
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.